[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Nippon Shinyaku Co. Ltd.

Nippon Shinyaku and Capricor Therapeutics announce positive Phase X results for Deramiocel, potentially leading to FDA approval and commercialization. However, near-term concerns regarding Viltepso remain.

### About Nippon Shinyaku Co. Ltd.
Nippon Shinyaku Co. Ltd. is a pharmaceutical company.  

### Insights
- Nippon Shinyaku Co. Ltd. creators is up XXXXXX% from the previous week.
- Nippon Shinyaku Co. Ltd. mentions is up XXX% from the previous week.
- Nippon Shinyaku Co. Ltd. Price hit a 52-Week high of $XXXXX for the hour
- Nippon Shinyaku Co. Ltd. Price hit an all time of $XXXXX for the hour

### Price: $
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/close.tsv)  
The recent price surge is likely driven by positive developments in the RGX-121 partnership with Capricor Therapeutics, overshadowing concerns related to the Uptravi patent cliff, as indicated by social media discussions and analyst ratings.  

1-Year High: $XXXXX on 2025-12-08  
1-Year Low: $XXXXX on 2025-07-14  
  
  
### AltRank: XXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/alt_rank.tsv)  
Nippon Shinyaku Co. Ltd. is currently AltRank #631 based on combined combined social and market metrics
Daily Average: XXX  
1-Year High: XXXXX on 2024-12-11  
1-Year Low: XXX on 2025-01-15  
  
  
### Galaxy Score: XX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/galaxy_score.tsv)  
Current Value: XX  
Daily Average: XX  
1-Year High: XX on 2025-01-14  
1-Year Low: XX on 2025-01-11  
  
  
### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XXX  
X Week: XXXXX +36,387%  
X Month: XXXXXX +6,125%  
X Months: XXXXXX -XX%  
X Year: XXXXXXX -XXXX%  
1-Year High: XXXXXX on 2025-01-14  
1-Year Low: X on 2025-04-24  

Engagements by network (24h):
X: XXX

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: X  
X Week: XX +325%  
X Month: XX no change  
X Months: XXX -XX%  
X Year: XXX +73%  
1-Year High: XX on 2025-02-06  
1-Year Low: X on 2024-12-18  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Nippon Shinyaku Co. Ltd. in the last XX hours which is no change from in the previous XX hours
Daily Average: X  
X Week: XX +233%  
X Month: XX -XX%  
X Months: XXX -XX%  
X Year: XXX +55%  
1-Year High: XX on 2025-02-06  
1-Year Low: X on 2024-12-18  

The most influential creators that mention Nippon Shinyaku Co. Ltd. in the last XX hours

| Creator                                        | Rank | Followers | Posts | Engagements |
| -------                                        | ---- | --------- | ----- | ----------- |
| [@avidresearch](/creator/twitter/avidresearch) | X    | XXXXXX    | X     | XXX         |

[View More](/list/creators/$4516t/100)
  
  
### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/sentiment.tsv)  
Current Value: XX%  
Daily Average: XX%  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% no change  
1-Year High: XXX% on 2024-12-29  
1-Year Low: XX% on 2025-09-18  

Most Supportive Themes:
- Capricor Therapeutics Partnership: (70%) Nippon Shinyaku's partnership with Capricor Therapeutics for the drug RGX-121 is generating significant positive attention, with multiple posts highlighting the potential value and clinical success of this collaboration.
- Stock Performance and Valuation: (20%) Discussions around Nippon Shinyaku's stock performance, including recent price surges and comparisons to its market cap relative to its drug revenue share with Capricor, are prominent.
  
Most Critical Themes:
- Patent Cliff Concerns: (10%) The Morgan Stanley downgrade due to the Uptravi patent cliff is a significant concern, potentially impacting future revenue streams and market position.
  
  
  
### Market Cap: $undefined
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$4516t/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$4516t/time-series/market_cap.tsv)  
Current Value: $undefined  
Daily Average: $XXXXXXXXXXXXXXX  
1-Year High: $XXXXXXXXXXXXXXX on 2024-12-17  
1-Year Low: $XXXXXXXXXXXXXXX on 2025-02-03  

### Top Nippon Shinyaku Co. Ltd. Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$DYN increases dystrophin in exon XX to XXXX% at month X. Mktcap $2.8B $WVE can deliver that with no renal adverse event risk (as shown in exon 53)"  
[X Link](https://x.com/avidresearch/status/1997999174223061413) [@avidresearch](/creator/x/avidresearch) 2025-12-08T11:58Z 11.7K followers, 3170 engagements


"$WVE definitely has X INHBE valuation built into it. 👇 Would argue its exon XX drug should justify most of its current valuation. They will be submitting WVE-N531 NDA to FDA next year. Vyondys XX from $SRPT and Viltepso from Nippon Shinyaku are X drugs approved for exon XX DMD. Both collectively bring in about $250M-$300M/yr (Viltepso brought in $70.8M in H1 2025). There are no other late stage players. $WVE drug is vastly superior to both of these approved drugs (just look at dystrophin levels) and will be monthly dosing option(vs weekly for X approved drugs)"  
[X Link](https://x.com/avidresearch/status/1997991378895138933) [@avidresearch](/creator/x/avidresearch) 2025-12-08T11:27Z 11.7K followers, 9652 engagements


"Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain"  
[X Link](https://x.com/Generic_Tina/status/1997827292417163681) [@Generic_Tina](/creator/x/Generic_Tina) 2025-12-08T00:35Z XX followers, XX engagements


"$TSE Nippon Shinyaku Co. Ltd. (TSE:4516) Stock Catapults XX% Though Its Price And Business Still Lag The Market - #stocks #news"  
[X Link](https://x.com/StockTickerZone/status/1996847069655716219) [@StockTickerZone](/creator/x/StockTickerZone) 2025-12-05T07:40Z 3942 followers, XXX engagements